Sawicka-Gutaj Nadia, Budny Bartłomiej, Zybek-Kocik Ariadna, Sowiński Jerzy, Ziemnicka Katarzyna, Waligórska-Stachura Joanna, Ruchała Marek
Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznań, Poland.
Endocrine. 2016 Aug;53(2):497-504. doi: 10.1007/s12020-015-0855-8. Epub 2016 Jan 14.
To investigate the role of NAMPT/visfatin in euthyroid patients with Graves' disease without (GD) and with Graves' ophthalmopathy (GO), we analyzed NAMPT leukocyte expression and its serum concentration. This was a single-center, cross-sectional study with consecutive enrollment. In total, 149 patients diagnosed with Graves' disease were enrolled in the study. We excluded subjects with hyper- or hypothyroidism, diabetes mellitus, other autoimmune disorders, active neoplastic disease, and infection. The control group was recruited among healthy volunteers adjusted for age, sex, and BMI with normal thyroid function and negative thyroid antibodies. Serum levels of visfatin, TSH, FT4, FT3, antibodies against TSH receptor (TRAb), antithyroperoxidase antibodies, antithyroglobulin antibodies, fasting glucose, and insulin were measured. NAMPT mRNA leukocyte expression was assessed using RT-qPCR. NAMPT/visfatin serum concentration was higher in GD (n = 44) and GO (n = 49) patients than in the control group (n = 40) (p = 0.0275). NAMPT leukocyte expression was higher in patients with GO (n = 30) than in GD patients (n = 27) and the control group (n = 29) (p < 0.0001). Simple linear regression analysis revealed that NAMPT/visfatin serum concentration was significantly associated with GD (β = 1.5723; p = 0.021). When NAMPT leukocyte expression was used as a dependent variable, simple regression analysis found association with TRAb, fasting insulin level, HOMA-IR, GD, and GO. In the stepwise multiple regression analysis, we confirmed the association between higher serum NAMPT/visfatin level and GD (coefficient = 1.5723; p = 0.0212), and between NAMPT leukocyte expression and GO (coefficient = 2.4619; p = 0.0001) and TRAb (coefficient = 0.08742; p = 0.006). Increased NAMPT leukocyte expression in patients with GO might suggest a presently undefined role in the pathogenesis of GO.
为了研究烟酰胺磷酸核糖转移酶/内脂素（NAMPT/visfatin）在无Graves眼病（GO）和有Graves眼病的甲状腺功能正常的Graves病（GD）患者中的作用，我们分析了NAMPT在白细胞中的表达及其血清浓度。这是一项单中心横断面研究，连续纳入研究对象。总共149例被诊断为Graves病的患者纳入本研究。我们排除了甲状腺功能亢进或减退、糖尿病、其他自身免疫性疾病、活动性肿瘤疾病和感染的患者。对照组从年龄、性别和BMI经过匹配、甲状腺功能正常且甲状腺抗体阴性的健康志愿者中招募。检测了内脂素、促甲状腺激素（TSH）、游离甲状腺素（FT4）、游离三碘甲状腺原氨酸（FT3）、促甲状腺激素受体抗体（TRAb）、抗甲状腺过氧化物酶抗体、抗甲状腺球蛋白抗体、空腹血糖和胰岛素的血清水平。使用逆转录定量聚合酶链反应（RT-qPCR）评估NAMPT mRNA在白细胞中的表达。GD患者（n = 44）和GO患者（n = 49）的NAMPT/visfatin血清浓度高于对照组（n = 40）（p = 0.0275）。GO患者（n = 30）的NAMPT在白细胞中的表达高于GD患者（n = 27）和对照组（n = 29）（p < 0.0001）。简单线性回归分析显示，NAMPT/visfatin血清浓度与GD显著相关（β = 1.5723；p = 0.021）。当将NAMPT在白细胞中的表达作为因变量时，简单回归分析发现其与TRAb、空腹胰岛素水平、稳态模型评估的胰岛素抵抗（HOMA-IR）、GD和GO相关。在逐步多元回归分析中，我们证实了较高的血清NAMPT/visfatin水平与GD之间的关联（系数 = 1.5723；p = 0.0212），以及NAMPT在白细胞中的表达与GO（系数 = 2.4619；p = 0.0001）和TRAb（系数 = 0.08742；p = 0.006）之间的关联。GO患者中NAMPT在白细胞中表达增加可能提示其在GO发病机制中目前尚未明确的作用。
